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Background: Since its introduction in the 1960s Anti-D immunoglobulin (Anti-D Ig) has been highly successful in
reducing the incidence of haemolytic disease of the fetus and newborn (HDFN) and achieving improvements to
maternal and fetal health. It has protected women from other invasive interventions during pregnancy and
prevented deaths and damage amongst newborns and is a technology which has been adopted worldwide. Currently
about one third of pregnant women with the blood group Rhesus D (RhD) negative in the UK (approximately 40,000
women per year in England and Wales), receive antenatal Anti-D Ig in pregnancy when they do not require it because
they are carrying a RhD negative fetus. Since 1997, a test using cell free fetal DNA (cffDNA) in maternal blood has been
developed to identify the genotype of the fetus and can be used to predict the fetal RhD blood group.
Discussion: This paper considers whether it is ethically acceptable to continue administering antenatal Anti-D Ig to all
RhD negative women when fetal RHD genotyping using maternal blood could identify those women who do not
need this product.
Summary: The antenatal administration of Anti-D Ig to a third of RhD negative pregnant women who carry a RhD
negative fetus and therefore do not need it raises important ethical issues. If fetal RHD genotyping using maternal
blood was offered to all RhD negative pregnant women it would assist them to make an informed choice about
whether or not to have antenatal Anti-D Ig.
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Currently about one third of pregnant women who are
blood group RhD negative in the United Kingdom (UK)
(approximately 40,000 women per year in England and
Wales [1]), receive antenatal Anti-D immunoglobulin
(Anti-D Ig) in pregnancy when they do not require it be-
cause they are carrying a RhD negative fetus [2]. The pur-
pose of administering Anti-D Ig is to reduce the chance of
sensitisation to RhD positive blood and so the potential
risks of haemolytic disease of the fetus and newborn
(HDFN). Since it is now possible to test maternal blood to
predict the RhD blood group of the fetus, our concern is
to ask whether it is ethically justifiable for this group of
women to continue to be offered Anti-D Ig? Further, while* Correspondence: Julie.Kent@uwe.ac.uk
1Department of Health & Social Sciences, University of the West of England,
Coldharbour Lane, Bristol BS16 1QY, UK
Full list of author information is available at the end of the article
© 2014 Kent et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the potential risks of HDFN are well established, and the
risks of receiving Anti-D Ig are very low, should we accept
that pregnant women and their RhD negative fetuses are
exposed to a plasma product sourced from non-local,
overseas donors where there are no clinical or other bene-
fits to the woman or the fetus?
Discussion
Administration of Anti-D Ig
Since its introduction in the 1960s Anti-D Ig has been
highly successful in reducing the incidence of HDFN
and achieving improvements to maternal and fetal
health. It has protected women from other invasive in-
terventions during pregnancy and prevented deaths and
damage amongst newborns and is a technology which
has been adopted worldwide. Yet there are international
and local variations in the pattern of its administration
[3]. In accordance with current UK NICE guidelines, [4]d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the UK are routinely offered Anti-D Ig prophylactically
(ie routine antenatal anti-D prophylaxis - RAADP) during
antenatal care (at 28 weeks), and following any antenatal
‘potential sensitising event’ (PSE) where fetal maternal
haemorrhage (FMH) may have occurred (including preg-
nancy termination). Anti-D Ig is also offered after the de-
livery but only when a cord blood test shows that the baby
is RhD positive. The above policies are designed to pre-
vent sensitisation in RhD negative women who carry a
RhD positive fetus and so antibody production arising to
HDFN in subsequent pregnancies with RhD positive fe-
tuses. The success of the above programme has led to the
incidence of HDFN now being relatively uncommon, al-
though some concern has been expressed about recent
cases [5]. If the fetus is RhD negative then in that preg-
nancy sensitisation and associated HDFN due to anti-D
cannot occur [6].
Non invasive prenatal testing of fetal genotype
Since 1997, [7] a test using cell free fetal DNA (cffDNA)
in maternal blood has been developed to identify the
genotype of the fetus and can be used to predict the fetal
RhD blood group. This was initially used in women who
had already been sensitised and so were at risk of HDFN
[8,9], however, from 2008 modifications were made to
allow a scaled-up high throughput approach [10]. Stand-
ardisation of the test has been the focus of international
research, and it has been shown to be very accurate but
the small possibility of false negative results remains. If
the test gave a false negative result and routine cord
blood phenotype testing at birth subsequently identified
the fetus as RhD positive then postnatal Anti-D Ig would
still be administered at that time, but potentially sensi-
tisation could occur in these women affecting subse-
quent pregnancies. The risks of this happening have
been estimated to be 1:86,000 [2]. In the UK, non-invasive
(or invasive) fetal blood group genotyping is currently only
performed when women’s samples are referred to the
NHS Blood and Transplant (NHSBT) or Scottish National
Blood Transfusion Service (SNBTS) [11] for testing to de-
termine the risk to the fetus when a mother is known to
have immune antibodies against the relevant blood group
antigen. A multicentre “research for patient benefit” NIHR
project has finished recruiting and is awaiting publication.
In addition a service implementation pilot that offers a
fetal genotyping test to all RhD negative women is now
underway in Bristol and Weston and results are expected
in late 2014 [12]. Only the Netherlands and Denmark cur-
rently offer this test to all RhD negative women in order
to identify those carrying a fetus that is RhD negative and
to reduce the unnecessary administration of Anti-D Ig
[13,14]. In Denmark, the decision was made concurrently
with the implementation of RAADP and it was recognisedthat the accuracy of fetal RHD genotyping was similar to
that of the cord blood RhD phenotyping used for the ad-
ministration of postnatal Anti-D Ig. In the Netherlands,
RAADP had already been established when fetal RHD
genotyping began to be offered to all RhD negative
women in 2011.
The production of Anti-D Ig
In the UK, polyclonal Anti-D Ig is a blood product man-
ufactured from pooled plasma, predominantly collected
from RhD negative male plasma donors in the United
States. These male donors are injected with RhD positive
red blood cells to stimulate sensitisation and antibody
production. The antibodies can then be harvested fol-
lowing plasmapheresis. A premium is paid to these men
in acknowledgement of the potential risks they face as a
result of injecting donor red blood cells prior to the dona-
tion session. The processing and fractionation of plasma
operates to industry standards and must comply with me-
dicinal product regulation in order to minimise the risks
of infection or viral transmission or contamination [15].
In the 1970s and 1990s, there were a number of con-
tamination episodes involving Anti-D Ig product in coun-
tries such as Ireland and Germany [16,17]. More recently,
the UK Royal College of Obstetricians and Gynaecologists
noted that: “There is no evidence to suggest that RAADP
is associated with adverse events that are of consequence
for the mother or baby, other than the possibility of blood-
borne infection (author’s emphasis), and procedures are in
place to minimise these risks” and to inactivate viruses
[18]. What is particularly troubling is that the risks of
prion transmission and newly emerging viruses are un-
known and therefore remain a potential risk for women
who continue to receive the product. In addition, adminis-
tration of Anti-D Ig and adverse incidents relating to its
use are a matter of concern for organisations such as Ser-
ious Hazards of Transfusion, [19] and concerns have re-
cently been raised about adverse incidents involving the
inappropriate and unnecessary administration of Anti-D
Ig to women who are RhD positive.
Ethical issues
Anti-D therapy has no direct benefit to the woman but
is designed to promote fetal health in future pregnancies.
The ethical (and legal) basis for current policy and prac-
tice is that women should be given appropriate informa-
tion about Anti-D Ig so that they are in a position to give
consent to the treatment. But on what basis are women
able to make such a decision when the RhD blood group
of their fetus remains unknown? Introduction of fetal
RHD genotyping to prevent unnecessary administration of
Anti-D Ig would be more consistent with existing policy
which is aimed at reducing wasteful use of blood and
blood products and ensuring that the right product is
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published cost analysis of mass fetal RHD genotyping sug-
gested that the costs of introducing such a service would
not be met by the reduction in use of prophylactic ante-
natal Anti-D Ig, [21] others have argue that automated
testing lowers assay costs below the price of Anti-D Ig
and is cost-effective [22]. There are inconsistencies in the
application of cost-analysis decision making within the
NHS. The highly precautionary approach now taken to
managing risks in a post-HIV blood contamination era
has meant that a range of values – ethical, social and polit-
ical – have influenced policy-making in relation to blood
safety, rather than relying predominantly on traditional
cost-benefit analysis in relation to healthcare interventions
[23]. So what values should underpin the policy that about
40,000 women per year in England and Wales continue to
receive a blood product they do not need?
We want to suggest that in addition to the audit of
Anti-D Ig use in England that is being undertaken by the
Royal College of Physicians and NHSBT as part of their
joint National Comparative Audit (NCA) program, a re-
view of the ethical issues involved is also needed [24].
Does the well accepted ethical principle that clinicians
should do no harm encompass the view that women
should not be given a blood product that does them no
good? Does consent to the administration of Anti-D Ig
also mean that women should first be offered fetal RHD
genotyping to establish their need for this product?
Current policy and practice in the UK to routinely admin-
ister Anti-D Ig emerged at a time when the technology of
fetal RHD genotyping was under-developed but a review
of the current approach is now timely given the develop-
ment of new capabilities to test fetal genotype. The wide-
spread adoption of the technology could ensure that
women, both in the UK and in other countries, do not re-
ceive a blood product unnecessarily. The ethical issues at
stake here include weighing the relatively low risks of false
negative results associated with fetal RHD genotyping
using cffDNA and the costs of implementing mass testing,
against the benefits of ceasing the practice of giving this
group of pregnant women a human blood product they
do not need.Summary
In short we have argued that, on ethical grounds, there
is a strong case for reviewing policy and practice relating
to the routine administration of prophylactic antenatal
Anti-D Ig. By making fetal RHD genotyping more widely
available, women would be better informed about whether
or not they need this blood product.Competing interests
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